Nutritional adequacy of goat milk infant formulas for term infants: a double-blind randomised controlled trial by Zhou, S. et al.
SUBMITTED VERSION  
 
Shao J. Zhou, Thomas Sullivan, Robert A. Gibson, Bo Loennerdal, Colin G. Prosser, 
Dianne J. Lowry, and Maria Makrides 
Nutritional adequacy of goat milk infant formulas for term infants: a double-blind 
randomised controlled trial 
The British Journal of Nutrition, 2014; 111(9):1641-1651 
 
 
© The Authors 2013 
 



























Content is made freely available by the author 
This is achieved by depositing the article on the author’s web page or in a suitable public repository, 
often after a specified embargo period. The version deposited should be the Accepted Manuscript. 
Publishers typically impose different conditions, but it should be noted that many OA mandates (such 
as the NIH public access policy) specify the Accepted Manuscript in their requirements unless the 
publisher allows the Version of Record. Refer to the table below for details. 
Summary of where an author published in a Cambridge Journal may deposit versions of their 
article 
 
11 August  2015 
 1
Title: Nutritional adequacy of goat milk infant formula for term infants:  a double-
blind randomised controlled trial  
 
Shao J Zhou1,2,5, Thomas Sullivan4, Robert A Gibson 5, Bo Lönnerdal6, Colin G 
Prosser7, Dianne J Lowry7, Maria Makrides1,2,3 
 
Author affiliation: 
1 Women’s & Children’s Health Research Institute, 72 King William Road, North 
Adelaide, SA 5006, Australia 
2 Department of Paediatrics & Child Health, Flinders Medical Centre, Bedford Park 
SA 5042, Australia  
3 School of Paediatrics & Reproductive Health, University of Adelaide, Adelaide, SA 
5005, Australia 
4 Data Management and Analysis Centre, Discipline of Public Health, University of 
Adelaide,  Adelaide, SA 5005, Australia 
5 School of Agriculture, Food & Wine, University of Adelaide, Waite Campus, Waite 
Road, Urrbrae, SA 5064, Australia 
6 University of California, Davis, USA  
7 Dairy Goat Co-operative (N.Z.) Ltd, Hamilton, New Zealand 
 
Corresponding author: 
Prof Maria Makrides 
Women’s & Children’s Health Research Institute   
72 King William Road, North Adelaide, SA 5006, Australia  
Telephone: +618 8161 6067 
Facsimile: +618 8239 0267 
E-mail: maria.makrides@health.sa.gov.au  
Reprints are not available from the authors 
 
Running title: Infant Goat formula, growth & nutrition 
Keywords: infant, growth, breastfeeding, formula, goat milk 
Clinical trial registry: Australian New Zealand Clinical Trials Registry 
(ACTRN12608000047392).
 2
Abstract  1 
The safety and nutritional adequacy of Goat milk infant formulae has been 2 
questioned. The primary objective of this study was to compare growth and 3 
nutritional status of infants fed goat milk infant formula with a typical whey based 4 
cow milk infant formula.   The secondary aim was to examine a range of health and 5 
allergy-related symptoms.  A double blind, randomised controlled trial with 200 6 
formula fed term infants randomly assigned to receive either goat or cow milk 7 
formula from 2 weeks until at least 4 months of age was conducted.  A cohort of 101 8 
breastfed infants was included for comparison.  Weight, length and head 9 
circumference were measured at 2 weeks, 1, 2, 3, 4, 6 and 12 months of age. 10 
Nutritional status was assessed from serum albumin, urea, creatinine, haemoglobin, 11 
ferritin, folate and plasma amino acids at 4 months. Z-scores for weight, length, head 12 
circumference and weight for length were not different between the two formula 13 
groups. There were differences between formula groups in some amino acids and 14 
blood biomarkers, but the mean values for biomarkers were within the normal 15 
reference range.  There were no differences in occurrence of serious adverse events, 16 
general health, incidence of dermatitis or medically diagnosed food allergy. The 17 
incidence of parental reports blood stained stools was higher in the goat milk formula 18 
group, although this was a secondary outcome and its importance is uncertain.  Goat 19 
milk formula provided growth and nutritional outcomes in infants that did not differ 20 
from a standard whey based cow milk formula.   21 
   22 
23 
 3
Appropriate nutrition during infancy is important not only for normal growth and 24 
development of the infant, but also for long term health outcomes. Breast feeding is 25 
recommended for delivering these short and long-term outcomes (1).  Infant formulas 26 
are used to supplement breast milk when breast milk is not sufficient or breastfeeding 27 
is not possible.  Cow milk infant formula is widely accepted as the first-line choice for 28 
healthy formula-fed infants.  These are typically based on cow milk proteins from 29 
skim milk and have extra whey proteins added to improve the profile of essential and 30 
semi-essential amino acids (2, 3).    31 
There is also consumer demand for goat milk infant formula as evidenced by 32 
widespread reports of the use of raw goat milk and homemade formula for infants (4-7).    33 
Goat infant formulae are manufactured in several countries.  Compositional analysis 34 
of an infant formula made from goat milk without added whey proteins suggests that 35 
the amino acid profile (8) is compatible with international standards for infant formula 36 
(9, 10).    This type of goat milk formula was also shown in animal studies to have 37 
similar digestibility and absorption of amino acids compared with a cow infant 38 
formula with added whey (11).  Thus, it was expected that the amino acid delivery to 39 
infants would be similar between the two formulae but this has never been tested. 40 
In addition to meeting compositional criteria it is important to establish the 41 
suitability and nutritional adequacy of infant formula containing new sources of 42 
proteins through clinical trials (9, 12).  While goat milk has high quality proteins and 43 
fats and has a history of use for human nutrition in many cultures (13-15), there has been 44 
only one previous randomised controlled trial (RCT) of infants fed goat milk infant 45 
formula (16).   This study showed that growth of 30 infants fed goat milk infant 46 
formula was similar to 32 infants fed a whey based cow milk infant formula (16).  47 
However, that study was insufficient for assessing the safety and nutritional adequacy 48 
of the goat milk formula because it was underpowered and lacked blood biochemical 49 
data (17).   50 
The primary aim of the present study was to compare growth and nutritional status 51 
of infants fed formulas either based on goat milk or cow milk in a well powered RCT.  52 
The secondary aim was to examine a range of health and allergy-related symptoms, 53 
including incidence and severity of dermatitis.  54 
 55 
Materials and methods  56 
 57 
 4
Participants  58 
The study population included two cohorts of infants who were either fed infant 59 
formula or were breastfed at the time of recruitment. Infants were eligible for 60 
inclusion in the study if the following inclusion criteria were met: 1) a healthy term 61 
infant with gestation of 37-42 weeks and birth weight ≥ 2.5 kg and  ≤ 4.75 kg; 2) aged 62 
up to 2 weeks; 3) mother was exclusively feeding infant formula within 2 weeks of 63 
birth (for formula cohort) or planned to exclusively breastfeed for at least 4 months 64 
(for the breastfed cohort).  Infants were excluded if they were from multiple births or 65 
had severe congenital or metabolic disease likely to affect infant feeding or infant 66 
growth. Infants who were exclusively formula fed or breastfed were identified and 67 
referred by midwives in the postnatal wards at one of three tertiary hospitals, the 68 
Women’s & Children’s Hospital, the Flinders Medical Centre or the Lyell McEwin 69 
Hospital in Adelaide, Australia.  The study was approved by the relevant Human 70 
Research Ethics Committees at all three study centres. Written informed consent was 71 
obtained from all participating families. The trial was registered with Australian New 72 
Zealand Clinical Trials Registry (ACTRN12608000047392). 73 
 74 
The nutrition composition of the study formulas 75 
The goat infant formula (GIF) was manufactured by Dairy Goat Co-operative (N.Z.) 76 
Ltd using whole goat milk without added whey proteins (final whey to casein ratio of 77 
approximately 20:80) and a blend of approximately 60% milk fat and 40% vegetable 78 
oils.  The control cow infant formula (CIF) consisted of cow skim milk and whey 79 
proteins (final whey to casein ratio of approximately 60:40) and vegetable oils as the 80 
source of fat and supplied by Nutricia (Auckland, New Zealand).  The protein to 81 
energy ratio of the both study formula was at the lower limit specified by CODEX (10) 82 
and similar to the low protein formula that is suggested to provide a more desired 83 
weight gain in infants (18).  The nutritional composition of both formulas is listed in 84 
Table 1.  85 
 86 
Study allocation and blinding   87 
Eligible formula fed infants were randomly assigned to GIF or CIF. Treatment 88 
allocation was through a web-based randomization service according to a computer 89 
generated randomization schedule, which was prepared by an independent statistician.     90 
Stratification was by sex and study centre and used variable block sizes of 4 and 8 in 91 
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equal proportions. The formulas were labeled in four different colors, two of them 92 
corresponding to GIF and the other two corresponding to CIF. Cans of both formulas 93 
were otherwise identical in appearance to maintain the blind.  This ensured that 94 
neither the parents nor the research staff were aware if the formula allocated was GIF 95 
or CIF. The blinding index was used to assess the success of blinding (19).   96 
 97 
Study intervention 98 
Parents and caregivers of formula fed infants were asked to feed their infants the 99 
allocated study formula from enrolment to at least four months of age and thereafter 100 
with other complementary foods up to 12 months of age.  Study formulas were 101 
supplied free of charge until 12 months of age. For breastfeeding infants, mothers 102 
were encouraged to continue exclusive breastfeeding for around four to six months of 103 
age in line with current recommendations.  Support for breastfeeding was provided by 104 
a qualified lactation consultant to mothers free of charge if needed. The timing of 105 
introduction of solids around 4 and 6 months was at the discretion of the families for 106 
both the formula fed and the breast fed infants.   107 
 108 
Outcome assessments 109 
The primary outcomes were infant weight, length and head circumference, measured 110 
at enrolment, 2 weeks and 1, 2, 3, 4, 6 and 12 months. All anthropometric growth data 111 
were converted to z-scores using WHO Child Growth Standards 112 
(http://www.who.int/childgrowth/en/). Secondary outcomes included nutritional 113 
status, general health, tolerance to formula and allergy symptoms.  114 
A small non-fasting blood sample (3-5 mL) was collected to assess blood 115 
biomarkers, including haemoglobin, packed cell volume (PCV) and serum creatinine, 116 
urea, albumin, ferritin, folate and plasma amino acids, at 4 months of age as indicators 117 
of general nutritional status. Iron deficiency anaemia was defined as haemoglobin < 118 
100 g/L & ferritin < 20 μg/L based on the diagnostic criteria of the test laboratory. 119 
Hemoglobin was measured spectrophotometrically by using a Cell Dyn 4000 analyzer 120 
(Abbott Laboratories, Santa Clara, CA), which has a coefficient of variation (CV) of  121 
<2%. Albumin, urea and ferritin were measured by Cobas/Hitachi Cobas C System, 122 
Cobas 6000 automated analyser (Roche Diagnostics, Indianapolis IN). Albumin was 123 
determined spectrophotometrically by an end-point BCG Dye-binding method. Urea 124 
was measured spectrophotometrically by an enzymatic method. The test method for 125 
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ferritin was particle enhanced immunoturbidmetry. The measurement of albumin and 126 
urea have CVs of <3% and ferritin has a CV <4%. Serum folate was analysed by 127 
ARCHITECT i optical system (Abbott) using the Chemiluminescent Microparticle 128 
Immunoassay (CMIA) Technology and has < 4% CV. Amino acids were measured on 129 
Hitachi L-8900 Amino Acid Analyser. Plasma samples (200 uL) were acidified with 130 
50 ul sulfosalicyclic acid to precipitate intact protein prior to analysis. The 131 
supernatant was mixed with lithium-diluent spiked with AE-Cys. The L-8900 Hitachi 132 
analyzer utilizes a lithium citrate buffer system and ion- exchange (Hitachicolumn) 133 
chromatography to separate amino acids followed by a "post-column" ninhydrin 134 
reaction detection system.  135 
At each growth assessment time point, parents/care givers were asked through a 136 
structured interview whether their infant had experienced any health problems 137 
including respiratory illness, gastro-intestinal illness, reflux, eye infection, ear, nose 138 
and throat conditions, fever, urinary tract infection and thrush.  Serious adverse 139 
events, defined as death or hospital admission > 24 hour during the 12 months study 140 
period, were also recorded.  141 
At the same time of growth assessments, incidence of dermatitis and its severity 142 
was assessed by trained research staff using SCORAD (20).  Food allergy was 143 
diagnosed by medical practitioners. Parents/care givers were also asked whether their 144 
infants had have symptoms related to food allergy and/or gastrointestinal function 145 
including hives, swelling of the face or body, wheeze/stridor, vomiting, loose watery 146 
stools, blood stained stools and itchy rash.   147 
Parents/care givers were asked to assess stool frequency, consistency and effort as 148 
indicators of tolerance to formula using the Bristol Stool Scale (21) as a guide. 149 
Sleeping patterns including length of each sleep, total number of sleeps during the 150 
day, and the length of time taken to settle for sleep during the day, in the evening or at 151 
night were also assessed by parental report based on the Sleep and Settle 152 
Questionnaire (22).  153 
 154 
Other assessments 155 
Demographic and baseline characteristics, including infant sex, weight and length at 156 
birth, age at enrolment, anthropometric measurements at enrolment, maternal age, 157 
BMI, parity, and history of smoking and drug and alcohol use during pregnancy were 158 
recorded at trial entry.  159 
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 160 
Sample size and power calculation  161 
Sample size calculations estimated that 64 infants per group were required to detect a 162 
0.5 SD difference (80% power with α=0.05) in weight (12).  We aimed to enrol 100 163 
infants per feeding group and 100 breastfed infants to provide reference data from a 164 
breastfed group. This sample size was also sufficient to detect a clinically important 165 
difference of 0.11 g/L (SD of 0.26g/L) in serum albumin, an indicator of protein 166 
adequacy, with 80% power (α=0.05). 167 
 168 
Statistical analysis  169 
All analyses were performed using SAS® Software version 9.2 or later (SAS Institute 170 
Inc., Cary, NC, USA). Blinded treatment codes were included in the database and 171 
analyses of the primary and secondary outcomes were performed blinded to treatment 172 
group. All analyses were performed using both intention-to-treat and per-protocol 173 
approaches, with infants who did not complete the trial or who had any non-study 174 
formula, liquids or solids for more than 12 days between 2 weeks and 4 months of age 175 
were excluded from the per-protocol analysis.  As the two analysis approaches 176 
produced similar results, only the primary intention-to-treat analyses are reported 177 
here.  178 
In order to minimize bias in the estimation of treatment effects due to missing data, 179 
multiple imputation was used to create 50 complete datasets for analysis. The 180 
parametric regression method was used to impute continuous variables and the 181 
logistic regression method was used for binary variables. In addition to the primary 182 
imputed analysis, sensitivity analyses were performed on the original data and on 183 
imputed data created using different seeds and using different imputation models. All 184 
approaches produced similar results, thus only the results of the primary imputed 185 
analysis are presented.  186 
Continuous outcomes measured at multiple assessments, including the primary 187 
anthropometric outcomes, were compared between formula and breastfeeding groups 188 
over time using linear mixed effects models. Fixed effects for group, time and the 189 
interaction between group and time were included in the models, while dependence 190 
was accounted for by allowing for correlated residuals within a child. Independent of 191 
the statistical significance of the interaction term, differences between groups were 192 
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reported separately at each time point, with the effects of treatment group expressed 193 
as mean differences. Continuous outcomes measured at a single time point were 194 
compared between groups using linear regression models, with the effects of group 195 
expressed as mean differences. Binary outcomes were analyzed using log binomial 196 
regression models, with the effects of group expressed as relative risks. Rare binary 197 
outcomes were analyzed using Fisher exact tests. Both unadjusted and adjusted 198 
analyses were performed, with conclusions on group differences being based on the 199 
adjusted analyses. For the primary growth outcomes, comparisons of the two 200 
randomised groups were adjusted for centre, while comparisons involving the 201 
breastfed reference group were adjusted for maternal education and the relevant 202 
anthropometric z-score at birth. All secondary outcomes were adjusted for the 203 
stratification variables centre and sex for comparisons of the randomised groups and 204 
maternal education and birth weight for comparisons involving the breastfed reference 205 
group. Due to imbalances in maternal smoking during pregnancy between the 206 
randomised groups, sensitivity analyses of the primary growth outcomes adjusting for 207 
centre and maternal smoking during pregnancy were also performed. All tests were 208 
two tailed with a significance level of P ≤ 0.05. 209 
 210 
Results 211 
Participants were recruited between April 2008 and April 2009 from three tertiary 212 
hospitals in Adelaide. Of the 1180 families who were approached to participate in the 213 
study, 768 were eligible and 301 (39%) consented. Two hundred infants were formula 214 
fed and 101 were breastfed. See the participant flow chart for more details (Figure 1).     215 
Maternal characteristics as well as infant anthropometrics at birth and at study 216 
entry are presented in Table 2. The mean age of infants at study entry was 6.2 ± 3.7 217 
(standard deviation) days and 46% were male. The baseline characteristics of the 218 
participants were comparable between the two formula groups, with the exception that 219 
the percentage of mothers who smoked during pregnancy was higher in the GIF group 220 
(45%) compared with the CIF group (34%). Compared with formula fed infants, the 221 
reference group of breastfed infants had a higher mean birth weight (p=0.001), lower 222 
maternal pre-pregnancy BMI (p < 0.0001), lower percentage of maternal smoking (p 223 
< 0.0001) during pregnancy and higher percentage of parents who completed higher 224 
education (p< 0.0001). The percentage of mothers who did not know their baby’s 225 
treatment group was similar between the groups (32% in the GIF group and 34% in 226 
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the CIF group). The blindness index, which indicates the percentage of mothers who 227 
guessed their treatment group correctly above chance, was 3.8% for the GIF group 228 
compared with 2.7% for the CIF group. 229 
The median (inter-quartile (IQ) range) daily intake of study formula ranged from 230 
698 ml (570 – 825 ml) in the first 2 weeks to 1000 ml (855 – 1190 ml) at 4 and 6 231 
months.  Seventy-five percent (76/101) of the breast fed infants, 73% (74/101) of 232 
infants in the GIF and 60% (59/99) in the CIF group were compliant with the 233 
definition of exclusive formula feeding or breast feeding (23)  from enrolment to 4 234 
months of age.  The level of compliance in the GIF was significantly different to CIF 235 
(p=0.02), but not significantly different to the breast fed reference group (p=0.37).   236 
 237 
Growth 238 
There were no differences between the two formula groups over the 12 month study 239 
period in the adjusted intention to treat analyses of weight (Figure 2a), length (Figure 240 
2b), head circumference (Figure 2c) and weight-for-length (Figure 2d) z-scores, with 241 
or without adjustment for baseline difference in maternal smoking. Also, gains in 242 
weight, length or head circumference from registration to 4 or 6 months did not differ 243 
between the two formula groups (data not shown).   244 
In comparison with breastfed infants, infants in the GIF group had higher weight z-245 
scores at 3, 4 and 6 months (mean difference 0.22, p=0.04; 0.30, p=0.005 and 0.33, 246 
p=0.003) while infants in the CIF group had higher weight z-scores from 2 to 12 247 
months of age (mean differences 0.22, p=0.04; 0.28, p=0.01; 0.39, p=0.001; 0.38, 248 
p=0.001 and 0.36, p=0.001). Infants in the GIF group had lower length z-scores at 2 249 
weeks and 1 month of age compared with breastfed infants (mean difference -0.33, 250 
p=0.003 and -0.37, p=0.001) whereas infants in the CIF group had higher length z-251 
scores at 4, 6 and 12 months of age (mean difference 0.25, p=0.03; 0.35, p=0.002 and 252 
0.25, p=0.03). While head circumference z-scores did not differ between the GIF 253 
group and breastfed infants, infants in the CIF group had higher z-scores at 2 and 6 254 
months of age compared with breastfed infants (0.24, p=0.04 and 0.3, p=0.01).  255 
Infants in the GIF group had higher weight-for-length z-scores compared with breast 256 
fed infants at 1 month only (mean difference 0.40, p=0.004), while weight-for-length 257 
z-scores were higher at 1 and 2 months in the CIF group (mean difference 0.46, 258 
p=0.001 and 0.39, p=0.006).  There were no statistically significant differences 259 
between formula and breast fed groups at any other times. 260 
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 261 
Biomarkers of nutritional status  262 
There were no differences in serum albumin, haemoglobin, PCV and ferritin between 263 
the two formula fed groups. No infants in either formula group had iron deficiency 264 
anaemia (defined as haemoglobin <100 g/L & ferritin < 20 μg/L). Infants in the GIF 265 
group had lower mean serum urea, creatinine and folate concentrations compared with 266 
infants in the CIF group (Table 3). Compared with breastfed infants, formula fed 267 
infants had higher mean serum urea concentrations, infants in the GIF group had 268 
lower mean serum folate concentration and, infants in the CIF group had higher mean 269 
folate concentrations (Table 3). The mean serum folate concentrations for all 3 groups 270 
of infants were within the normal reference range for infants of this age (24).   271 
Concentrations of essential and semi-essential amino acids in plasma of infants are 272 
presented in Figure 3.  Valine and phenylalanine were higher and isoleucine and 273 
threonine were lower in plasma of infants fed GIF compared with CIF.  The mean 274 
difference (95% confidence interval (CI)) for valine was 37 (25, 50) μg/L, 275 
phenylalanine was 5 (0, 10) μg/L, isoleucine -9 (-16, -3) μg/L and threonine -32 (-45, 276 
-18) μg/L.   All other essential and semi-essential amino acids in plasma of formula 277 
fed infants did not significantly differ between groups.   278 
Compared with breast fed infants, infants fed GIF had significantly higher 279 
concentrations of lysine, methionine, phenylalanine, threonine and valine.  Mean 280 
differences (95% CI) were 15 (1, 29) μg/L, 6 (4, 9) μg/L, 13 (7, 18) μg/L, 13 (7, 18) 281 
μg/L, 19 (4, 34) μg/L and 66 (52, 79) μg/L, respectively.  Isoleucine, leucine, lysine, 282 
methionine, phenylalanine, threonine and valine were all higher in plasma of infants 283 
fed CIF compared with breast fed infants. Mean differences (95% CI) were 13 (7, 20) 284 
μg/L, 11 (2, 21) μg/L, 19 (6, 33) μg/L, 6 (3, 8) μg/L, 8 (2, 13) μg/L, 51 (37, 66) μg/L 285 
and 29 (15, 44) μg/L, respectively.  No amino acids were lower in either formula 286 
group compared with breast fed infants. 287 
 288 
General health and allergy-related outcomes 289 
There were no differences in the risk between the two formula groups of an adverse 290 
health condition, including respiratory, gastro-intestinal illness, reflux, eye infection, 291 
ear, nose and throat conditions, fever, urinary tract infection and thrush. There were 292 
also no differences in the risk between the formula groups and the breastfed reference 293 
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group for the above health conditions, with the exception that more infants had oral 294 
thrush in the CIF group compared with the breastfed reference group (9/86 vs. 2/99, 295 
p= 0.02) during the 12 month study period. The proportion of infants who had any 296 
serious adverse events during the 12 month study period was similar between the GIF, 297 
CIF and breastfed reference groups: 15/101 (14.9%), 12/99 (12.1%) and 9/101 298 
(8.9%), respectively (p=0.43).  The most common serious adverse events were 299 
bronchiolitis and other respiratory infections. No infants died. 300 
The proportions of infants with medically diagnosed food allergy (GIF 2/92 vs. 301 
CIF 1/89 vs. breast fed 5/99) or dermatitis assessed using SCORAD (GIF 13/91 vs. 302 
CIF 20/86 vs. BF 21/99) did not differ between groups. The mean SCORAD score of 303 
infants with dermatitis was 9.9 + 6.7 for GIF, 11.9 + 7.1 for CIF and 11.1 + 6.3 for 304 
breast fed groups (mean + SD).   305 
There was no difference between the formula groups in the proportion of infants 306 
with parental reported symptoms that related to allergy and/or gastrointestinal 307 
function, except for parentally reported blood stained stools (Table 4).  Compared 308 
with breastfed infants, infants in the GIF group had a higher risk of blood stained 309 
stools while infants in the CIF group had a higher risk of wheeze (Table 4).  The 310 
proportions of infants with hives (GIF 5/89 vs CIF 5/86 vs BF 6/99), swelling of the 311 
face (GIF 6/89 vs. 6/86 vs. BF 5/99) did not differ between all groups in simple 312 
unadjusted analyses.  313 
 314 
Formula tolerance 315 
The mean number of stool motions per day in infants from the GIF group at 2 weeks, 316 
1, 2 and 3 months of age were  2.5 + 1.6, 2.0 + 1.3, 1.6 + 1.0 and 1.6 + 0.9 (mean + 317 
SD), respectively.  These were not different from the stool frequency of infants in the  318 
CIF group, which were 2.5 + 1.4, 2.0 + 1.4, 1.5 + 0.9 and 1.6 + 1.3 at 2 weeks, 1, 2 319 
and 3 months, respectively.  However, stool frequency in both formula groups were  320 
significantly lower (p<0.001) than the breast fed group  (6.3 + 3.3, 5.0 + 2.3, 3.0 + 2.2 321 
and 2.4 + 1.8 at 2 weeks, 1, 2 and 3 months, respectively). Compared with the CIF 322 
group infants in the GIF had lower  mean  stool consistency scores at 2 weeks (GIF 323 
4.69 ± 1.44 vs. CIF 5.46 ± 0.96, p < 0.0001) and 1 month (GIF 4.95 ± 1.35 vs. CIF 324 
5.35 ± 1.19, p = 0.01).  No differences in the stool consistency score were observed at 325 
other assessment time points.  326 
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There were no differences in the mean length of each sleep or the total number of 327 
sleeps between the two formula groups, with the exception that infants in the GIF 328 
group had a shorter mean length of each sleep in the evening (GIF 103 ± 63 vs. CIF 329 
127 ± 65 minutes, p=0.007) and a longer mean length of each sleep at night (GIF 317 330 
± 96 vs. CIF 288 ± 102 minutes, p=0.03) at the 2 month assessment. The mean length 331 
of time taken to settle for sleep during the day, in the evening or at night also did not 332 
differ between GIF and CIF groups. In comparison with breastfed infants, there were 333 
some differences in sleeping patterns between the formula fed and the breastfed 334 
infants, but the differences were inconsistent (data not shown).  335 
 336 
Discussion 337 
This study is the first to rigorously evaluate in healthy term infants the effect of 338 
feeding of goat infant formula to 12 months on growth, nutritional status, oral 339 
tolerance and a wide range of health and allergy related outcomes in a well conducted 340 
RCT involving a control group fed cow milk infant formula and a reference group of 341 
breastfed infants.  We could detect no difference in z-scores for infant weight, length, 342 
head circumference and weight-for-length up to 12 months between the two formula 343 
groups.  The same overall treatment effects were observed from intention to treat or 344 
per-protocol analysis that excluded data from infants who received any non-study 345 
formula, liquids or solids for more than 12 days before the four months of age.  This 346 
suggests it is unlikely that the use of non-study foods by some infants within the first 347 
four months had a significant impact on the outcomes of the study. We did detect 348 
some differences in weight and weight-for-length z-scores for both formula fed 349 
groups compared with breastfed infants, consistent with other studies comparing 350 
growth of formula and breastfed infants (25-27). Interestingly while the differences in 351 
weight or weight for length z-scores persisted at 12 months between breastfed infants 352 
and  infants fed cow milk formula in our study, consistent with the other cow milk 353 
based formula studies (25-27) , there was no differences between infants fed goat milk 354 
formula and breastfed infants. Our  study used the same formula with a lower protein 355 
content (2 g/100 kcal and 2.1 g/100 Kcal for goat and cow milk formula, respectively) 356 
through to 12 months rather than switching to a follow-on formula with higher protein 357 
content from 6 months as occurred in the other formula studies (25-27). This may partly 358 
explain the difference observed between our study and the other formula studies 359 
mentioned above as it has been shown that weight for length z-score at 24 months of 360 
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infants fed low protein formula was not different to breast fed infants while infants 361 
fed high protein formula (2.9 g/ 100 kcal) had higher z-score. 362 
There were minor differences in the blood biomarkers between the formula fed 363 
groups, which likely reflected differences in the composition of the two formulae.  364 
For instance, the cow infant formula contained added folate close to the recommended 365 
maximum, compared with the goat milk formula that had an amount in the mid-range 366 
of the recommendations (9, 10).  Nevertheless, concentrations of blood biomarkers 367 
measured at four months were within the normal reference range for infants of this 368 
age (24). 369 
Whey proteins are often added to formula to help improve protein quality and 370 
availability of essential and semi-essential amino acids (28, 29).  Infant formula made 371 
from goat milk without added whey proteins was shown to have sufficient quantities 372 
of all the essential and semi-essential amino acids (8) and similar digestion and 373 
absorption of the amino acids in an animal model compared with a whey based cow 374 
infant formula (11).  The present study shows some differences in plasma amino acids 375 
profile between the formula groups as well as in comparison with the breastfed 376 
infants, but there were large inter-individual variations. Although the differences were 377 
statistically significant, they are unlikely to be clinically important as the mean 378 
plasma amino acid concentration of infants in both formula groups are comparable 379 
with those reported in other studies (30, 31).  380 
This study is the first to record a wide range of outcomes related to general health, 381 
gastrointestinal function and allergy when infants were exposed to goat infant formula 382 
using a combination of objective clinical assessments and subjective parental reports. 383 
There were no differences in objective assessments of allergy related outcomes 384 
including dermatitis and medically diagnosed food allergy.   385 
The only statistically significant finding between the formula groups was a greater 386 
number of parental reports of blood stained stools in infants fed goat compared with 387 
cow infant formula. We are unsure about the significance of this finding. Firstly, the 388 
number of reports of blood stained stools were low overall and secondly, there was no 389 
indication of other gastrointestinal disorders, differences in stool characteristics, 390 
crying and sleeping patterns, general health or other allergy-related symptoms. 391 
Furthermore, none of the infants in the study had iron deficiency anaemia which 392 
would indicate no significant blood loss over time. Finally, the outcomes related to 393 
allergy and gastrointestinal function were secondary outcomes, which the study did 394 
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not have adequate power to rigorously assess, and thus they need to be interpreted 395 
with caution as it is possible that this may due to chance.  A much larger, adequately 396 
powered RCT with objective assessment of clinical outcomes and biomarkers of 397 
allergy is needed to rigorously evaluate the effects of goat milk infant formula on 398 
allergy and gastrointestinal function.  399 
In conclusion, growth and blood biomarkers of nutritional status of infants fed a 400 
whole goat milk based infant formula did not differ from infants fed standard cow 401 
infant formula with added whey.  The lack of significant difference between the 402 
formula groups for an extensive range of health related outcomes and for the 403 
occurrence of serious adverse events support the safety of the goat milk for infant 404 
formula.   405 
 406 
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biochemistry and 
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7 Families withdrew  
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taken 
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80 infants included in 
analysis of blood 
biochemistry and 
plasma amino acids  
101 infants included 
in analysis of growth  
 
82 infants included in 
analysis of blood 
biochemistry and 
plasma amino acids  
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Table 1. Nutritional composition of the two infant formulas used in the study.   
  Goat milk formula Cow milk formula Mature human milk1 
Nutrient Unit Per 100 mL Per 100 mL Per 100 g 
Energy2 kcal 65.6 64.8 70 
  kJ 274.0 271.0                291 
   Per 100 kcal Per 100 kcal Per 100 g 
Protein g 2.0 2.1 1.0 
Fat g 5.3 5.2 4.4 
   Saturated fat  g 2.0 2.0 - 
   Unsaturated fat g 3.3 3.2 - 
   Linoleic acid ώ6 g 0.6 0.9 - 
   α-Linolenic acid ώ3 g 0.1 0.1 - 
Carbohydrate g 11.0 11.0 6.9 
Vitamins     
Vitamin A (RE) μg 141.0 87.0 61 
Vitamin D3 μg 1.8 2.1 0.1 
Vitamin E (TE) mg 2.6 1.1 0.08 
Vitamin K1 μg 12.0 8.8 - 
Vitamin C mg 20.0 12.0 5 
Thiamine μg 118.0 58.0 10 
Riboflavin μg 226.0 250.0 40 
Niacin mg 1.3 0.8 0.18 
Vitamin B6 μg 80.0 65.0 - 
Folic acid μg 12.0 21.0 5.03 
Pantothenic acid mg 0.6 1.2 0.22 
Vitamin B12 μg 0.3 0.5 0.05 
Biotin μg 3.8 4.7 - 
Minerals     
Calcium mg 98.0 81.0 32 
Phosphorus mg 73.0 53.0 14 
Sodium mg 31.0 31.0 17 
Potassium mg 133.0 116.0 51 
Chloride mg 116.0 71.0 - 
Magnesium mg 10.0 10.0 3 
Iron mg 1.0 1.3 Trace 
Zinc mg 0.9 0.7 0.2 
Iodine μg 15.0 17.0 - 
Copper μg 76.0 70.0 0.1 
Manganese μg 16.0 12.0 - 
Selenium μg 1.9 3.7 1.8 
Inositol mg 6.8 5.1 - 
Choline mg 27.0 19.0 - 
Taurine mg 8.9 6.6 - 
Carnitine mg 1.2 3.3 - 
1Reference: Wijesinha-Bettoni, R & Burlingame, B. Chapter 3. Milk and dairy products 
composition. In: Muehlhoff, E, Bennett, A & McMahon, D eds. Milk and dairy products in 
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human nutrition. FAO 2013.  2The energy content was calculated based on 14 g powder 
added to 100 mL water. 3Folate 
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Table 2.  Characteristics of participants. 
 
GIF (n=101) CIF (n=99) BF (n=101) 
P-value2 
(FF vs. BF) 
Maternal characteristics     
Age (y) 27.8 ± 6.61 28.2 ± 5.8 30.7 ± 5.2 0.0002 
Race, Caucasian [n (%)] 
 
92 (91) 94 (95) 93 (92)  
Education [n (%)]    <0.0001 
Secondary incomplete 30 (30) 36 (36) 10 (10)  
Certificate/diploma or 
secondary complete 
65 (64) 58 (59) 50 (50)  
Degree or higher degree 6 (6) 5 (5) 41 (41)  
BMI (kg/m2) 26.6 ± 6.3 27.8 ± 7.6 24.6 ± 4.5 0.0007 
Smoking in pregnancy [n (%)] 45 (44.6) 34 (34.3) 10 ( 9.9) <0.0001 
Infant 
Birth characteristics 
   
 
Sex, M [n (%)] 48 (47.5) 45 (45.5) 44 (43.6) 0.63 
GA at birth (wk) 39.4 ± 1.0 39.3 ± 1.1 39.6 ± 1.0 0.048 
Birth weight (g) 3379 ± 466 3407 ± 419 3564 ± 409 0.001 
Birth length (cm) 49.5 ± 2.0 49.3 ± 2.1 50.2 ± 2.0 0.003 
Birth head circumference (cm) 34.7 ± 1.4 34.6 ± 1.5 35.1 ± 1.2 0.01 
Baseline data      
Age at enrolment (d) 6.0 ± 3.6 6.1 ± 3.7 6.5 ± 3.8 0.35 
Weight at enrolment (g) 3345 ± 452 3371 ± 423 3491 ± 447 0.01 
Length at enrolment (cm) 50.0 ± 2.0 49.9 ± 2.1 50.9 ± 2.0 0.0001 
Head circumference at 
enrolment (cm) 
35.0 ± 1.2 35.1 ± 1.4 35.5 ± 1.3 0.009 
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1Mean ± SD (all such values); 2Continuous and categorical characteristics compared using 
independent samples t-tests and chi-square tests respectively; GIF: goat milk infant formula; 
CIF: cow milk infant formula; FF: formula fed; BF: breastfed. GA: gestational age 
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 (95% CI)  













Albumin (g/L) 44.6 ± 2.21 44.7 ± 2.5 45.5 ± 2.8 -0.1 (-0.9, 0.7) 0.82 -1.0 (-1.9, 0) 0.04 -0.9 (-1.8, 0.1) 0.07 
Creatinine 
(mmol/L) 
17.0 ± 3.2 19.0 ± 3.3 18.5 ±3.4 -2.0 (-3.1, -0.9) 0.0004 -1.0 (-2.3, 0.2) 0.09 1.0 (-0.2, 2.2) 0.09 
Haemoglobin 
(g/L) 
114 ± 9 116 ± 9 116 ±10 -2 (-5, 1) 0.19 -1.5 (-5.1, 2.2) 0.43 0.7 (-2.9, 4.2) 0.71 
PCV 0.34 ± 0.03 0.35 ± 0.03 0.35 ± 0.04 -0.01 (-0.02, 0.00) 0.10 -0.01 (-0.02, 0.01) 0.27 0 (-0.01, 0.01) 0.74 
Urea (mmol/L) 2.8 ± 0.5 3.1 ± 0.6 2.4 ± 0.7 -0.3 (-0.5, -0.1) 0.01 0.4 (0.1, 0.6) 0.001 0.6 (0.4, 0.8) <.0001 
Folate (nmol/L) 30.7 ± 5.6 42.1 ± 3.9 36.5  ± 5.5 -11.4 (-13.2, -9.5) <0.0001 -6.7 (-8.7, -4.7) <.0001 4.7 (2.8, 6.7) <.0001 
Ferritin (μg/L) 100 ± 70 92 ± 60 114 ± 83 1.1 (0.8, 1.5) 0.65 0.9 (0.7, 1.3) 0.66 0.9 (0.6, 1.2) 0.31 
GIF: goat milk infant formula; CIF: cow milk infant formula; BF: breastfed; CI: confidence interval. PCV: packed cell volume. 
1Mean ± SD (all such values).   
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Table 4. Incidence of parental reports food allergy/gastrointestinal symptoms in the 12 month study period 
 
GIF CIF BF 
Relative risk 
 (95% CI) 








CIF vs. BF 
 
P 
 n/N n/N n/N       
Wheeze/stridor 43/94 49/91 30/100 0.88 (0.66, 1.17) 0.37 1.37 (0.93, 2.03) 0.12 1.57 (1.07, 2.3) 0.02 
Vomiting  81/94 79/94 79/100 1.03 (0.92, 1.15) 0.57 1.11 (0.98, 1.26) 0.11 1.09 (0.94, 1.26) 0.24 
Loose watery stool 72/93 77/92 81/100 0.92 (0.8, 1.06) 0.26 0.9 (0.76, 1.07) 0.23 0.95 (0.82, 1.12) 0.56 
Blood stained stools  17/90 7/86 7/100 2.39 (1.05, 5.48) 0.04 3.81 (1.67, 8.69) 0.01 1.57 (0.56, 4.42) 0.39 
Itchy rash 32/91 35/87 37/100 0.87 (0.6, 1.27) 0.47 1.05 (0.7, 1.58) 0.80 1.21 (0.82, 1.78) 0.34 
Other skin problems 14/91 18/87 16/99 0.76 (0.4, 1.43) 0.39 1.18 (0.56, 2.48) 0.67 1.58 (0.76, 3.27) 0.22 
GIF: goat milk infant formula; CIF: cow milk infant formula; BF: breastfed; CI: confidence interval. 
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Figure 2. Weight (a), length (b), head circumference (c) and weight-for-length (d) z-scores of 
infants fed goat milk formula (triangle), cow milk formula (solid circle) or breast milk (open 
circle).  Z-score data were based on WHO reference data and values are mean +/- SD of 
imputed data.  * Statistically significant difference between goat formula and breast milk 
groups.  ** Statistically significant difference between cow formula and breast milk groups. 
Statistically significant at p<0.05.  




Figure 3. Mean (+/-SD) concentrations of essential and semi-essential amino acids in plasma 
of infants after 4 months of being fed goat milk formula ( open bars), cow milk formula (gray 
bars) groups or breast milk (closed bars).  a: significant difference between formula groups.  
b: significant difference goat formula and breast milk groups.  c: significant difference cow 
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